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INTRODUCTION
Endoscopic mucosal resection (EMR) is emerging as one
of the most important techniques to be incorporated into
gastrointestinal endoscopy (1). However, en bloc resection is
often not achieved using conventional techniques such as
the strip biopsy or cap EMR (2). In an attempt to overcome
this limitation, endoscopic submucosal dissection (ESD) tech-
niques using a variety of knives, such as the insulated-tip or
the triangle-tip models, have been developed (3-5). ESD can
completely remove affected mucosa by dissecting through
the middle or deeper part of the submucosa (6). The large
specimen extending into the submucosa attained by submu-
cosal dissection techniques permits definitive pathological
assessment of resection margins and invasion depth even for
large tumors greater than 20 mm in diameter. This would
almost certainly result in a lower recurrence rate than piece-
meal resection (1). 
ESD can achieve a complete resection in a majority of pa-
tients, but it is associated with a higher risk of bleeding than
classic EMR (7). Although bleeding during ESD is usually
treated with procedures such as electrocoagulation and hemo-
clipping and poses no clinical problem, postoperative or de-
layed bleeding, on the other hand, has been reported other-
wise (8). Prevention of bleeding after ESD is therefore an
important clinical issue. For preventing bleeding after ESD,
histamine2-receptor antagonists (H2RAs) or proton pump
inhibitors (PPIs) have been administered. However, few stud-
ies have been made to investigate the effectiveness of H2RAs
or PPIs for preventing bleeding after ESD. Therefore, the
aim of this study was to compare the relative effectiveness of
pantoprazole and famotidine for the prevention of delayed
bleeding after ESD. 
MATERIALS AND METHODS
We conducted a prospective, randomized, single-blind
comparative trial. All patients undergoing ESD for gastric
neoplasm between September 2005 and September 2006
were included in this prospective study. They were random-
ly assigned, before gastric ESD, to pantoprazole or famoti-
dine medication. In  the pantoprazole group, pantoprazole 80
mg (a loading dose) was given intravenously 2 hr before ESD,
and 8 mg/hr of intravenous pantoprazole was given contin-
uously for the first 24 hr (maintenance). At the second day,
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A Prospective Randomized Trial of Either Famotidine or Pantoprazole
for the Prevention of Bleeding after Endoscopic Submucosal Dissection
Endoscopic submucosal dissection (ESD) has been reported to have a higher bleed-
ing rate than conventional methods. However, there are few reports on whether a
proton pump inhibitor or a histamine2-receptor antagonist is the more effective
treatment for preventing bleeding after ESD. In a prospective trial, patients under-
going ESD due to gastric adenoma or adenocarcinoma were randomly assigned
to pantoprazole or famotidine. Both drugs were given intravenously for the first 2
days, thereafter by mouth. Eighty-five in the pantoprazole group and 79 in the famo-
tidine group were included for analysis. Primary outcome measure was the delayed
bleeding rate. Clinical characteristics were not different between the two groups.
The delayed bleeding rate was significantly lower in the pantoprazole group com-
pared with the famotidine group (3.5% vs. 12.7%, p=0.031). On multivariate anal-
ysis, the preventive use of pantoprazole (relative hazard: 0.220, 95% CI: 0.051-
0.827, p=0.026) and the specimen size (≥ ≥34 mm, relative hazard: 4.178, 95%
CI: 1.229-14.197, p=0.022) were two independent factors predictive of delayed
bleeding. There were no significant differences in en bloc and complete resection
rate between the two groups. In conclusion, pantoprazole is more effective than
famotidine for the prevention of delayed bleeding after ESD.
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pantoprazole 40 mg was given intravenously twice. From
the third day after ESD, pantoprazole 40 mg was adminis-
tered orally for 8 weeks. In the famotidine group, famotidine
20 mg was given intravenously twice daily for 2 days, start-
ing 2 hr before ESD. From the third day after ESD, famoti-
dine 20 mg was administered orally twice daily for 8 weeks.
The indications for ESD were followings: gastric adenoma
(no limitation in size) and an early gastric adenocarcinoma
(well or moderately differentiated; size <2 cm if elevated,
<1 cm if depressed; no ulceration; and no lymph node in-
volvement or metastasis by CT) (6). Patients were excluded
if they had a previous history of upper gastrointestinal sur-
gery or vagotomy; known hypersensitivity to pantoprazole
or famotidine; current use of aspirin, non-steroidal anti-inflam-
matory drugs, or corticosteroids. Possible complications of
ESD were discussed with the patients and their relatives,
and written informed consent was obtained before entry into
the trial. The Ethics Committee of Chonnam National Uni-
versity Hospital approved the treatment protocol. The allo-
cation of patients to treatment was done by drawing sequen-
tially numbered envelopes, each containing a previously
determined, randomly selected assignment based on a table
of random numbers. 
Investigations before ESD
Demographic and clinical characteristics, including age
and gender, were recorded. The location, size, and histopa-
thological type of lesions were recorded before ESD. Patients
were evaluated for Helicobacter pylori infection by rapid ure-
ase test and endoscopic biopsy specimens. Biopsy specimens
were stained with H&E and Giemsa. The presence of H.
pylori infection was considered negative only if rapid urease
test and biopsy specimen were both negative.
ESD
ESD was performed by endoscopic submucosal dissection
method using an insulated-tip diathermic knife for en bloc
resection. After the procedure, the size of tissue specimen,
any immediate complications, and histopathologic findings
were recorded. ESD was considered complete when the neo-
plastic tissue was circumferentially surrounded by mucosal
and submucosal non-neoplastic tissue (2). ESD was consid-
ered to be incomplete when neoplastic tissue was present at
the mucosal and/or submucosal margins of the ESD speci-
men and no additional resections at the periphery of tumor
had been taken that showed tumor-free margins on histo-
logic examination (2). Bleeding encountered during ESD
was termed immediate, and bleeding after ESD was termed
delayed (8). After ESD, patients were observed for vital signs
and complete blood counts. Delayed bleeding was suspect-
ed as one or more of the ongoing bleeding signs including
fresh hematemesis, hematochezia, instability of vital signs,
or a reduction of hemoglobin by more than 2 g/dL after ESD.
When delayed bleeding was suspected, immediate endoscopy
was performed. Endoscopic findings determined to indicate
bleeding after ESD were 1) active bleeding during re-endo-
scopy; 2) exposed vessels and/or fresh clots that were not seen
immediately after initial ESD; and 3) evident increase in clots
in stomach at the re-endoscopy compared with ESD (10). If
bleeding or visible vessel was found during ESD and re-endo-
scopy, thermal coagulation or endoscopic hemoclipping was
performed as required. The delayed bleeding rate as a prima-
ry outcome was compared between two groups, and imme-
diate bleeding rate, en bloc resection rate, complete resection
rate, need for surgery, and mortality, as secondary outcomes,
were also compared between two groups. Follow-up endoscopy
was performed at 1 month and 3 months after ESD to check
the healing process of the ulcer.
Statistical analysis
Continuous data were summarized as mean (95% confidence
interval [CI]). The Student t-test was utilized to compare the
mean values of continuous variables. The chi-square test with
Yates’ correction for continuity and the Fisher’s exact test were
utilized as appropriate for the comparison of categorical vari-
ables. Univariate and forward stepwise multivariate logistic
regression analysis were performed to assess the potential pre-
dicting factors of delayed bleeding after ESD. The analysis was
performed with statistical software package (SPSS 12.0 version
for Windows, SPSS, Chicago, IL, U.S.A.). A p value less than
0.05 was accepted as statistically significant. This study hypoth-
esized a reduction of delayed bleeding rate from 20% to 5% by
acid suppression therapy. According to the sample size calcu-
lation, the study would require 76 patients in each group. The
type I error and type II error were set to 0.05 and 0.2, respec-
tively.
RESULTS
During the study period, a total of 176 patients were en-
rolled and randomly assigned equally to the two groups.
Among them, 8 patients (2 in pantoprazole group and 6 in
famotidine group) were excluded from the final analyses be-
cause they were lost to follow-up. Four patients (1 in the pan-
toprazole group and 3 in the famotidine group) were exclud-
ed because of a failure to meet the requirements of the final
analyses. The cause of exclusion in the pantoprazole group was
no loading dose. The cause of exclusion in the famotidine group
was current medication of PPIs. Finally, 85 patients in the
pantoprazole group and 79 patients in the famotidine group
were analyzed. Data regarding the clinical and endoscopic
features of the patients are outlined in Table 1. There were no
significant differences between two groups with respect to
age, gender, comorbidity, histology, location of lesion, posi-Pantoprazole for the Prevention of Bleeding After ESD 1057
tive H. pylori, lesion size, specimen size, and procedure time.
A summary of clinical outcome data is outlined in Table
2. There was no significant difference in the immediate bleed-
ing rate during ESD between the two groups (62.4% vs.
57.0%, p>0.05). However, the delayed bleeding rate after ESD
was significantly lower in the pantoprazole group than in
the famotidine group (3.5% vs. 12.7%, p=0.031). Immedi-
ate bleeding and delayed bleeding were controlled and stop-
ped by electrocoagulation and/or hemoclipping. None of
the patients indicated major bleeding requiring surgery. Most
of delayed bleeding occurred within 7 days after ESD (11/13,
84.6%). The use of pantoprazole was very effective in pre-
venting bleeding within 24 hr after ESD (0% vs. 6.3%, p=
0.024). Active bleeding (spurting or oozing) was noted in
7/13 (53.8%) of the patients. There were no differences in
the en bloc resection rate, complete resection rate, perforation
rate, necessity of surgery, and mortality between two groups.
Delayed gastric perforation was found in one famotidine-treat-
ed patient on the third day after ESD, and he was promptly
treated by surgery. Two patients in each group underwent
surgery due to vertical margin-positive adenocarcinoma in
the resection specimen. During follow-up, no significant side
effects induced by drug administration were found in either
treatment groups.
Univariate analysis (Table 3) showed that the delayed bleed-
ing was significantly related to the use of preventive panto-
prazole (relative hazard: 0.252, p=0.042), adenocarcinoma
(relative hazard: 3.765, p=0.026), and specimen size (≥34
mm, relative hazard: 3.652, p=0.030). On multivariate analy-
sis, the use of preventive pantoprazole (relative hazard: 0.220,
95% CI: 0.051-0.827, p=0.026) and specimen size (≥34
mm, relative hazard: 4.178, 95% CI: 1.229-14.197, p=0.022)
were two independent predicting factors of delayed bleed-
ing (Table 4).
DISCUSSION
EMR shows a promising therapeutic option for the removal
of early-stage gastric cancer because it is less invasive for pa-
tients compared with surgery. To accomplish ultimate cure







Age (yr) 62.9 (9.4) 63.5 (7.8) 0.645
Gender (M/F) 52/33 53/26 0.431
Comorbidity (%)  39 (45.9%) 33 (41.8%) 0.596
Hypertension 24 21
Diabetes mellitus 4 6
Angina pectoris 2 2
Asthma 2 4
Chronic liver disease 3 1
Others 6 3
Histology (%) 0.163
Adenoma 71 (83.5%) 59 (74.7%)
Adenocarcinoma 14 (16.5%) 20 (25.3%)
Location (%) 0.700
Body 26 (30.5%) 22 (27.8%)
Antrum 59 (69.5%) 57 (72.2%)
H. pylori (+, %) 52 (61.9%) 50 (64.1%) 0.772
Lesion size (mm) 18.1 (6.9) 18.8 (8.7) 0.546
Specimen size (mm)  31.1 (9.5) 31.1 (10.0) 0.443
Procedure time (min)   29.2 (21.4) 26.8 (22.3) 0.477







Immediate bleeding (%)  53 (62.4%) 45 (57.0%)  0.482
Delayed bleeding (%) 3 (3.5%) 10 (12.7%) 0.031
<24 hr 0 (0%) 5 (6.3%) 0.024
<7 days 2 (2.3%) 4 (5.1%) 0.430
<2 weeks 1 (1.2%) 1 (1.3%) 1.000
Stigmata of delayed bleeding (%) 0.569
Spurting 0 (0%) 2 (20.0%)
Oozing 2 (66.7%) 3 (30.0%)
Exposed vessels without  0 (0%) 2 (20.0%)
bleeding
Black spots and clots without  1 (33.3%) 3 (30.0%)
bleeding
En bloc resection (%) 74 (88.1%) 70 (88.6%) 0.919
Complete resection (%) 80 (94.1%) 72 (94.7%) 0.864
Perforation (%)  0 (0%) 1 (1.3%) 0.971
Surgery (%) 2 (2.4%) 3 (3.8%) 0.934
Mortality (%) 0 (0%) 0 (0%) 1.000 








Preventive pantoprazole  0.252 0.067-0.954 0.042
Female 1.123 0.350-3.602 0.846
Age (yr) 1.005 0.942-1.073 0.875
Comorbidity 0.906 0.291-2.824 0.906
Adenocarcinoma 3.765 1.174-12.072 0.026
Lesion size 0.969 0.908-1.034 0.340
Specimen size (≥34 mm) 3.652 1.134-11.766 0.030
Location 0.707 0.186-2.689 0.611
En bloc resection 2.512 0.626-10.092 0.194
Procedure time 0.992 0.970-1.014 0.460
H. pylori (+) 1.068 0.333-3.427 0.912
Immediate bleeding 4.046 0.867-18.888 0.075









Preventive pantoprazole  0.220 0.051-0.827 0.026
Specimen size (≥34 mm) 4.178 1.229-14.197 0.022
Table 4. Multivariate analysis of potential predicting factors for
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by EMR, en bloc resection is critical for gastric neoplasm
because it may permit accurate histologic diagnosis, defini-
tive pathological assessment of resection margins and inva-
sion depth, and prediction of presence of lymph node
metastasis. ESD is a new EMR technique, which has major
advantages in comparison with conventional EMR; first, no
limitations in location and shape of the lesion; second, en bloc
resection is possible even in a large tumor; and third, the
tumors with ulcer also are resectable (9). Although ESD can
increase en bloc and complete resection rate and may reduce
the local recurrence rate, ESD has been reported to have a
higher bleeding rate than conventional EMR (7). In ESD, the
rate of bleeding after the procedure was reported to be 7% to
38% (3, 10-13). A larger and deeper artificial ulceration by
ESD is believed to increase the risk of bleeding in compari-
son with classic EMR. 
In general, PPIs or H2RAs are used for inducing rapid heal-
ing of artificial gastric ulcers after EMR. An intragastric pH
of greater than 6 has been shown to lower the risk of recur-
rent bleeding in patients with bleeding peptic ulcers (14). An
intravenous bolus followed by continuous-infusion PPI is effec-
tive in decreasing rebleeding in patients who have undergone
successful endoscopic therapy (15, 16). PPIs are known to be
more potent at elevating the intragastric pH than H2RAs.
Therefore, it can be assumed that PPIs in duce ulcer healing
more rapidly and prevent bleeding episodes more efficiently
than H2RAs after ESD. However, to date there have been
no studies indicating the effectiveness of PPIs or H2RAs for
preventing bleeding after ESD. In a recent study, no difference
was found between famotidine and omeprazole in bleeding
rates after EMR (17). In that study, bleeding after EMR was
seen in five (17.9%) of the 28 patients treated with famoti-
dine and in four (13.8%) of the 29 patients treated with ome-
prazole (17). However, in the present study, the delayed bleed-
ing rate after ESD was significantly lower in the pantopra-
zole group than in the famotidine group (3.5% vs. 12.7%,
p<0.05). There are several possible explanations for these dif-
ferences in the delayed bleeding rate. First, the sample size in
the previous study was relatively small (28 patients in the
famotidine group and 29 patients in the omeprazole group).
Second, this may be because of the difference of PPI regimen.
The dose of omeprazole (20 mg, I.V., twice a day) was only
40 mg for the first day of EMR in the previous study, but the
dose of pantoprazole (initial 80 mg bolus injection, followed
by 8 mg/hr continuous infusion) was 280 mg for the first day
of ESD in the present study. It has been already known that
the median pH of 6.3 could be achieved by 80 mg+8 mg/hr
pantoprazole infusion (18). Therefore, 80 mg+8 mg/hr pan-
toprazole infusion is more useful for preventing bleeding th-
rough clot stabilization at an elevated gastric pH. And, a sin-
gle oral dose of pantoprazole, 40 mg, resulted in significant-
ly more inhibition of gastric acid secretion than omeprazole,
20 mg, over a 24-hr period (19).
In the present study, 80 mg+8 mg/hr pantoprazole infu-
sion was used only in the first day of ESD, and then 40 mg
pantoprazole was used intravenously twice in the second
day. In patients after EMR, the risk of delayed bleeding is
highest mainly within 24 hr after EMR (20). Therefore, the
assumption of the current study was that 80 mg+8 mg/hr
pantoprazole infusion in the first day of ESD would have the
most important clinical significance for preventing bleed-
ing after ESD. In this study, the use of 80 mg+8 mg/hr pan-
toprazole infusion is very effective in preventing bleeding
within 24 hr after ESD (0% vs. 6.3%, p=0.024).
In the present study, the delayed bleeding rate within 24 hr
after ESD was significantly lower in the pantoprazole group
than in the famotidine group. Several factors, including loca-
tion, lesion size, specimen size, EMR method, histologic
type of gastric tumors, and presence of immediate bleeding,
have been implicated in bleeding by EMR (20-22). The dis-
tribution of these factors was similar in both groups in the
present study. ESD was performed only by endoscopic sub-
mucosal dissection method using an insulated-tip diather-
mic knife in both groups. Therefore, the difference in the
delayed bleeding rate within 24 hr after ESD is unlikely to
have been influenced by these factors. 
In the present study, the use of preventive pantoprazole
(relative hazard: 0.220) and specimen size (≥34 mm, rela-
tive hazard: 4.178) were two independent predicting factors
of delayed bleeding (Table 4). A larger and deeper artificial
ulceration by ESD was easy to bleed because bleeding inci-
dence may depend on the size of the specimen (23). And, a
recent study demonstrated that PPIs may be superior to
H2RAs in terms of converting active stage ulcers into the
healing stage, especially in case with a large iatrogenic ulcers
after ESD (24). The present study also suggests that PPIs may
be more effective than H2RAs for preventing bleeding after
ESD by inducing rapid healing of large artificial ulcers. How-
ever, in the present study, high-dose PPI was compared
with usual-dose famotidine. Therefore, larger clinical tirals
comparing high-dose PPI and high-dose famotidine (or
usual-dose PPI and usual-dose famotidine) should be per-
formed to find the best effective method for preventing
delayed bleeding after ESD.
In the present study, there was no significant drug inter-
action in either groups. Extensive analyses have demonstrat-
ed that famotidine has no clinically significant interactions
with theophylline, diazepam, or phenytoin (25). These
results are consistent with famotidine’s very limited ability
to alter the activity of cytochrome P450 isoenzymes (25).
Pantoprazole did not interact with digoxin, nifedipine, theo-
phylline, diazepam, warfarin, phenytoin, or oral contracep-
tives (26). Pantoprazole has been reported to have few clini-
cal significant drug-drug interactions (26).
In conclusion, pantoprazole is more effective than famoti-
dine for the prevention of delayed bleeding after ESD.REFERENCES
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